Renal effects of levosimendan: A consensus report

Cardiovascular Drugs and Therapy

Volumn 27, Issue 6, 2013, Pages 581-590

  Yilmaz, Mehmet B ^a   Grossini, Elena ^b   Silva Cardoso, José C ^c   Édes, István ^d   Fedele, Francesco ^e   Pollesello, Piero ^f   Kivikko, Matti ^f   Harjola, Veli Pekka ^g   Hasslacher, Julia ^h   Mebazaa, Alexandre ⁱ   Morelli, Andrea ^e   Le Noble, Jos ^j   Oldner, Anders ^k   Erroz, Ignacio Oulego ^l   Parissis, John T ^m   Parkhomenko, Alexander ⁿ   Poelzl, Gerhard ^o   Rehberg, Sebastian ^p   Ricksten, Sven Erik ^q   Rodríguez Fernández, Luís M ^l   Salmenperä, Markku ^g   Singer, Mervyn ^r   Treskatsch, Sascha ^s   Vrtovec, Bojan ^t   Wikström, Gerhard ^u   more..

^a CUMHURIYET UNIVERSITY   (Turkey)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c University of Porto   (Portugal)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Orionintie 1   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

^j VIECURI MEDICAL CENTER   (Netherlands)

^k KAROLINSKA INSTITUTE   (Sweden)

^l Complejo Asistencial Universitario de León   (Spain)

^m NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁿ Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^p UNIVERSITY OF MÜNSTER   (Germany)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^t UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^u UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Levosimendan; Renal dysfunction

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FENOLDOPAM; HTK SOLUTION; ILOPROST; LEVOSIMENDAN; MILRINONE; N ACETYL BETA GLUCOSAMINIDASE; NORADRENALIN; PIMOBENDAN; PLACEBO; UREA; VASOPRESSIN;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ANTIOXIDANT ACTIVITY; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CREATININE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EUROPE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY VASCULAR RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; SYSTOLIC HEART FAILURE; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; KIDNEY; PYRIDAZINES;

EID: 84892373432     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6485-6     Document Type: Review

References (52)

1. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135-42.
2. Kallel S, Triki Z, Abdenadher M, Frikha I, Jemel A. Karoui a [acute renal failure after cardiac surgery: evaluation of the RIFLE criteria]. Nephrol Ther. 2013;9:108-14.
3. Oppert M, Engel C, Brunkhorst F-M, Bogatsch H, Reinhart K, Frei U, et al. Acute renal failure in patients with severe sepsis and septic shock-a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008;23:904-9.
4. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-8.
5. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-10.
6. Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82-7.
7. Landoni G, Mizzi A, Biondi-Zoccai G, Bruno G, Bignami E, Corno L, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2010;24:51-7.
8. Nieminen MS, Pollesello P, Vajda G, Papp Z. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009;53:302-10.
9. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-6.
10. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol. 1996;119:609-15.
11. Faivre V, Kaskos H, Callebert J, Losser M-R,Milliez P, Bonnin P, et al. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology. 2005;103:514-21.
12. Oldner A, Konrad D,Weitzberg E, Rudehill A, Rossi P,Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med. 2001;29:2185-93.
13. Grossini E,Molinari C, Pollesello P, Bellomo G, Valente G,Mary D, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342:376-88.
14. ZagerRA, Johnson AC, Lund S,Hanson SY, AbrassCK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453-62.
15. Rehberg S, Ertmer C, Vincent J-L, Spiegel H-U, Kohler G, Erren M, et al. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock. Crit Care Med. 2010;38:2016-23.
16. Neary P, Redmond HP. Ischemia-reperfusion injury and the systemic inflammatory response syndrome. In: Grace PA, Mathie RT, editors. Ischemia-reperfusion injury. London: Blackwell Science; 1999. p. 123-36.
17. Sucu N, Unlu A, Tamer L, Aytacoglu B, Coskun B, Bilgin R, et al. Effects of trimetazidine on tissue damage in kidney after hindlimb ischemia-reperfusion. Pharmacol Res. 2002;46:345-9.
18. Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, et al. Management of acute cardiac failure by intracoronary administration of levosimendan. J Cardiovasc Pharmacol. 2011;58:246-53.
19. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
20. Soeding PF, Crack PJ, Wright CE, Angus JA, Royse CF. Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial K(ATP) channel and potential pERK 1/2 activation. Eur J Pharmacol. 2011;655:59-66.
21. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005;7:882-7.
22. Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, Grossini E. Levosimendan modulates programmed forms of cell death through K(ATP) channels and nitric oxide. J Cardiovasc Pharmacol. 2011;57:246-58.
23. Yakut N, Yasa H, Bahriye Lafci B, Ortac R, Tulukoglu E, Aksun M, et al. The influence of levosimendan and iloprost on renal ischemiareperfusion: an experimental study. Interact Cardiovasc Thorac Surg. 2008;7:235-9.
24. Louhelainen M, Merasto S, Finckenberg P, Vahtola E, Kaheinen P, Leskinen H, et al. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. J Physiol Pharmacol. 2009;60:41-7.
25. Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan comparedwith dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
26. Silva-Cardoso J, Ferrreira J, Oliveira-Soares A, Martins-de-Campos J, Fonseca C, Lousada N, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol. 2009;28:143-53.
27. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail. 2007;13:417-21.
28. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431-5.
29. Yilmaz MB, Yontar C, Erdem A, Karadas F, Yalta K, Turgut OO, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009;24:16-21.
30. Zorlu A, Yucel H, Yontar OC, Karahan O, Tandogan I, Katrancioglu N, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537-43.
31. Caira C, Brasolin B, Maestrini V, Scardala R, Orvieto G, Mancone M, et al. 475 Effects of Levosimendan on renal function and renal hemodynamic parameters in patients with acute heart failure. Eur J Heart Fail Suppl. 2007;6:103.
32. PackerM, ColucciW, Fisher L, MassieWM, Teerlink JR,Young J, et al. For the REVIVE heart failure study group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103-11.
33. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on renal blood flow, glomerular filtration rate, renal oxygen consumption and oxygenation after cardiac surgery: a randomized controlled study. Crit Care Med, In press.
34. Eriksson HI, Jalonen JR, Heikkinen LO, KivikkoM, Laine M, Leino KA, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87:448-54.
35. Ristikankare A, Poyhia R, Eriksson H, Valtonen M, Leino K, Salmenpera M. Effects of levosimendan on renal function in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth. 2012;26:591-5.
36. Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006;20:353-7.
37. Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O, et al. [Hemodynamic effects of levosimendan following cardiac surgery]. Rev Esp Anestesiol Reanim. 2005;52:389-94.
38. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol. 2004;44:703-8.
39. Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. [The calciumsensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol. 2008;61:471-9.
40. Morelli A, De Castro S, Teboul J-L, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31:638-44.
41. Morelli A, Ertmer C, Pietropaoli P,WestphalM. Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function? Curr Drug Targets. 2009;10:863-71.
42. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-8.
43. Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98:1489-92.
44. Poelzl G, Zwick RH, Grander W, Metzler B, Jonetzko P, Frick M, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33:368-73.
45. Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37:3017-23.
46. Lorenz JN, Schnermann J, Brosius FC, Briggs JP, Furspan PB. Intracellular ATP can regulate afferent arteriolar tone via ATPsensitive K+channels in the rabbit. J Clin Invest. 1992;90:733-40.
47. Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Dopamine increases renal oxygenation: a clinical study in postcardiac surgery patients. Acta Anaesthesiol Scand. 2010;54:183-90.
48. Appel RG, Wang J, Simonson MS, Dunn MJ. A mechanism by which atrial natriuretic factor mediates its glomerular actions. Am J Physiol. 1986;251:1036-42.
49. Morgan CJ, Gill PJ, Lam S, Joffe AR. Peri-operative interventions, but not inflammatory mediators, increase risk of acute kidney injury after cardiac surgery: a prospective cohort study. Intensive CareMed. 2013;39:934-41.
50. Gecit I, Kavak S,YukselMB, Basel H, Bektas H, Gumrukcuoglu HA et al. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health. 2012.
51. Chew MS, Hawthorne WJ, Bendall J, Whereat S, Huang S, Ting I, et al. No beneficial effects of levosimendan in acute porcine endotoxaemia. Acta Anaesthesiol Scand. 2011;55:851-61.
52. Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care. 2011;15:R166.